← Leaderboards
Dai Fukumura
Massachusetts General Hospital
$13,639,390
Attributed
$14,758,582
Total exposure
10
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,758,582 · 10
By mechanism
R01$7,206,587 · 3
P01$6,875,589 · 5
R21$416,818 · 1
S10$259,588 · 1
Top collaborators
- Rakesh K. Jain6 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Rakesh K. Jain$48,476,214
- Lance L Munn$15,934,149
- Mikael Pittet$14,206,093
- Robyn S Klein$18,056,082
- Ralph Weissleder$110,468,710
Others in their field
Top investigators on “Blood Vessels”
- Sonia M Thomas · Research Triangle Institute$353,402,726
- Tracy L Nolen · Research Triangle Institute$353,402,726
- Charles Decarli · University Of California At Davis$66,498,201
- Josef Coresh · New York University School Of Medicine$63,693,760
- Sterling C Johnson · St. Joseph'S Hospital And Medical Center$62,000,770
- Robert P Kimberly · University Of Alabama At Birmingham$56,093,149
Research focus
Blood VesselsTumorIn VivoNeoplastic CellCellsMolecularAngiogenesisPhysiologicalSolid NeoplasmResponseHypoxiaMediatingPathway InteractionsMonitorOrganVascular Endothelial Growth FactorsSignal TransductionIntravital MicroscopyCytokineStromal CellsInfiltrationNovel StrategiesBaseCancer Cell
Grant awards (51)
Improving CAR-T cell therapy in metastatic breast cancers by reprogramming obesity-aggravated tumor microenvironment via physical activity$416,818
R21 · FY2025 · CA · contact PI
Reprogramming the Tumor Microenvironment to Improve Immunotherapy of Glioblastoma by Co-Targeting VEGF and Ang2$363,077
R01 · FY2025 · NS · contact PI
Reprogramming the Tumor Microenvironment to Improve Immunotherapy of Glioblastoma by Co-Targeting VEGF and Ang2$391,317
R01 · FY2024 · NS · contact PI
Reprogramming the Tumor Microenvironment to Improve Immunotherapy of Glioblastoma by Co-Targeting VEGF and Ang2$403,419
R01 · FY2023 · NS · contact PI
Reprogramming the tumor microenvironment to improve immunotherapy of glioblastoma by co-targeting VEGF and Ang2$403,419
R01 · FY2022 · NS · contact PI
Reprogramming the tumor microenvironment to improve immunotherapy of glioblastoma by co-targeting VEGF and Ang2$403,419
R01 · FY2021 · NS · contact PI
Reengineering obesity-induced abnormal microenvironment to improve PDAC treatment$477,379
R01 · FY2020 · CA · contact PI
Reengineering obesity-induced abnormal microenvironment to improve PDAC treatment$463,057
R01 · FY2019 · CA · contact PI
Reengineering obesity-induced abnormal microenvironment to improve PDAC treatment$477,379
R01 · FY2018 · CA · contact PI
Reengineering obesity-induced abnormal microenvironment to improve PDAC treatment$162,720
R01 · FY2018 · CA · contact PI
Reengineering obesity-induced abnormal microenvironment to improve PDAC treatment$495,129
R01 · FY2017 · CA · contact PI
Reengineering obesity-induced abnormal microenvironment to improve PDAC treatment$162,720
R01 · FY2017 · CA · contact PI
Surgical and Animal Core$436,627
P01 · FY2016 · CA · contact PI
Overcoming Resistance to Anti-VEGF Treatment of Colorectal Cancers$262,738
P01 · FY2016 · CA · contact PI
Surgical and Animal Core$442,242
P01 · FY2015 · CA · contact PI
Overcoming Resistance to Anti-VEGF Treatment of Colorectal Cancers$262,738
P01 · FY2015 · CA · contact PI
Surgical and Animal Core$428,138
P01 · FY2014 · CA · contact PI
Overcoming Resistance to Anti-VEGF Treatment of Colorectal Cancers$254,248
P01 · FY2014 · CA · contact PI
Surgical and Animal Core$424,010
P01 · FY2013 · CA · contact PI
Overcoming Resistance to Anti-VEGF Treatment of Colorectal Cancers$246,978
P01 · FY2013 · CA · contact PI
Surgical and Animal Core$437,672
P01 · FY2012 · CA · contact PI
Nitric Oxide in Tumor Angiogenesis, Microcirculation and Radiation Therapy$302,174
R01 · FY2012 · CA · contact PI
Overcoming Resistance to Anti-VEGF Treatment of Colorectal Cancers$263,367
P01 · FY2012 · CA · contact PI
Nitric Oxide in Tumor Angiogenesis, Microcirculation and Radiation Therapy$302,174
R01 · FY2011 · CA · contact PI
Surgical and Animal Core$406,023
P01 · FY2010 · CA · contact PI
Vascular Normalization: Rolse of Perivascular Cells$377,880
P01 · FY2010 · CA · contact PI
Nitric Oxide in Tumor Angiogenesis, Microcirculation and Radiation Therapy$311,520
R01 · FY2010 · CA · contact PI
Doppler Optical Frequency Domain Imaging Instrument$259,588
S10 · FY2010 · RR · contact PI
Surgical and Animal Core$400,296
P01 · FY2009 · CA · contact PI
Vascular Normalization: Rolse of Perivascular Cells$368,668
P01 · FY2009 · CA · contact PI
Nitric Oxide in Tumor Angiogenesis, Microcirculation and Radiation Therapy$310,803
R01 · FY2009 · CA · contact PI
Surgical and Animal Core$379,503
P01 · FY2008 · CA · contact PI
Vascular Normalization: Rolse of Perivascular Cells$355,053
P01 · FY2008 · CA · contact PI
Nitric Oxide in Tumor Angiogenesis, Microcirculation and Radiation Therapy$309,082
R01 · FY2008 · CA · contact PI
Surgical and Animal Core$392,289
P01 · FY2007 · CA · contact PI
Vascular Normalization: Rolse of Perivascular Cells$350,785
P01 · FY2007 · CA · contact PI
NO in Tumor Angiogenesis,Microcirculation & Rad.Therapy$288,015
R01 · FY2006 · CA · contact PI
Surgical and Animal Core$199,066
P01 · FY2006 · CA · contact PI
Vascular Normalization: Rolse of Perivascular Cells$187,268
P01 · FY2006 · CA · contact PI
NO in Tumor Angiogenesis,Microcirculation &Rad.Therapy$294,946
R01 · FY2005 · CA
NO in Tumor Angiogenesis,Microcirculation &Rad.Therapy$294,946
R01 · FY2004 · CA
NO in Tumor Angiogenesis,Microcirculation &Rad.Therapy$294,946
R01 · FY2003 · CA
NO in Tumor Angiogenesis,Microcirculation &Rad.Therapy$294,946
R01 · FY2002 · CA
Core--Surgical and animal$0
P01 · FY2002 · CA
Angiogenesis µcirculation: tumor/host interaction$0
P01 · FY2002 · CA
Core--Surgical and animal$0
P01 · FY2001 · CA
Angiogenesis µcirculation: tumor/host interaction$0
P01 · FY2001 · CA
Angiogenesis µcirculation: tumor/host interaction$0
P01 · FY2000 · CA
Core--Surgical and animal$0
P01 · FY2000 · CA
Core--Surgical and animal$0
P01 · FY2000 · CA
Angiogenesis µcirculation: tumor/host interaction$0
P01 · FY2000 · CA